Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $103

Benzinga · 15h ago
Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $119 to $103.